Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

    (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDyTWM2OD13Lki2OlYh|ryP MVHTRW5ITVJ?
DOHH-2 MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;Wb4xmUUN3ME25MlM2Pjh7IN88US=> M{DWV3NCVkeHUh?=
no-10 M1nLSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTlwOUCzPUDPxE1? Mn7sV2FPT0WU
LS-513 MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu0TWM2OD1zMT6zOVQ4KM7:TR?= MUnTRW5ITVJ?
ALL-PO NEC0VXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTFzLke3N|Qh|ryP MUXTRW5ITVJ?
8-MG-BA M2PFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7vd29mUUN3ME2xN{4yOTJ|IN88US=> M4P0fnNCVkeHUh?=
RPMI-8402 M3r1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlGxTWM2OD1zNT64OVM4KM7:TR?= Mn:xV2FPT0WU
EoL-1-cell MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37BTWlEPTB;MUiuOVk1QCEQvF2= MX;TRW5ITVJ?
NALM-6 M4jjZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF7LkCxOlch|ryP M3ewPHNCVkeHUh?=
DEL NWnYTIhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJyLkG0O|Eh|ryP MofvV2FPT0WU
SR MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvpVpprUUN3ME2yN{43PzF3IN88US=> MUfTRW5ITVJ?
697 MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJ4Lk[xOVUh|ryP NVfZSo0xW0GQR1XS
COLO-829 M4[1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnPOZRKSzVyPUK2Mlg1QDNizszN MnXaV2FPT0WU
EVSA-T MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\VV4dVUUN3ME2yO{42PTZzIN88US=> MnKxV2FPT0WU
ATN-1 NVu2eZd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTNzLkKzNlkh|ryP MonhV2FPT0WU
L-363 MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTNzLke0OlEh|ryP NHvBVWhUSU6JRWK=
LAMA-84 M3n6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvtXJRKSzVyPUOyMlUzOTFizszN NXG1S3cyW0GQR1XS
NOS-1 NFTkNHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofTTWM2OD1|ND6yPVU3KM7:TR?= NXTHZZU1W0GQR1XS
BB30-HNC M1L4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTN2LkOzNFYh|ryP MV3TRW5ITVJ?
BC-1 NVrobFNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULvPFR4UUN3ME2zO{46PzR4IN88US=> NXfZcpZrW0GQR1XS
IST-SL2 MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fORmlEPTB;M{iuNlI1KM7:TR?= M{n2fXNCVkeHUh?=
D-392MG M37DUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTrXWVKSzVyPUSwMlIzOTVizszN MkXVV2FPT0WU
no-11 MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDWPJBLUUN3ME20NE42PTJzIN88US=> NYDWSXRQW0GQR1XS
LC4-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP6OVNKSzVyPUSwMlg4OTZizszN MUXTRW5ITVJ?
A388 MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP6boNKSzVyPUSyMlU5PDhizszN NUDWco4zW0GQR1XS
NTERA-S-cl-D1 NEnNfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPDR41KSzVyPUSyMlcxPzRizszN MWjTRW5ITVJ?
CESS M1PMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojCTWM2OD12ND6yNlMzKM7:TR?= M{nUS3NCVkeHUh?=
RS4-11 NEfycZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfmW2xKSzVyPUS5MlA6OzhizszN NF3DV2NUSU6JRWK=
MS-1 NGLnO|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i1R2lEPTB;NUCuPVM2OSEQvF2= NXrFS4k4W0GQR1XS
CTV-1 M1q0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInLZmJKSzVyPUWxMlA4PCEQvF2= M{nNWnNCVkeHUh?=
D-502MG MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX2NZBmUUN3ME21NU43OjdzIN88US=> MWjTRW5ITVJ?
ML-2 M1\rXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT1Um9qUUN3ME21Nk46OTl3IN88US=> MlLkV2FPT0WU
SK-NEP-1 Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;FXYliUUN3ME21N{4{QTJ|IN88US=> NYPLTpM2W0GQR1XS
LOXIMVI MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2S4[WlEPTB;NUOuOVg5PCEQvF2= NF:5U5ZUSU6JRWK=
DJM-1 NIm1dpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq3ZphKSzVyPUW2MlM{QTFizszN NFfy[JRUSU6JRWK=
GI-1 MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\mTWM2OD13Nj62NVQ6KM7:TR?= NV\1dZBqW0GQR1XS
IST-MES1 Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTZyLkW0PVMh|ryP MX3TRW5ITVJ?
MV-4-11 MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTZyLk[1N|gh|ryP NVq3b5hXW0GQR1XS
OVCAR-4 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXENFMyUUN3ME22N{42PjV5IN88US=> Mn32V2FPT0WU
KE-37 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTZ4LkK2Olgh|ryP NInscI1USU6JRWK=
D-542MG M1PUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzEcFJKSzVyPU[4MlQyOzVizszN NIL2N|JUSU6JRWK=
MHH-PREB-1 MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn5RVZKSzVyPUeyMlg1PDFizszN NFvFOHlUSU6JRWK=
MRK-nu-1 M3;hRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof6TWM2OD15Mz60O|A2KM7:TR?= M4LPdnNCVkeHUh?=
D-247MG NG\SbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\LTWM2OD15Mz61OFQzKM7:TR?= NVn2XWNbW0GQR1XS
OCI-AML2 NXPIdm9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTTbGJKSzVyPUe2Mlk{PjlizszN M3z6NHNCVkeHUh?=
LP-1 Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLuPYdKSzVyPUiyMlg4OzFizszN NFrwb5VUSU6JRWK=
HCC1599 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\2TWM2OD16ND6yPFM4KM7:TR?= MkXBV2FPT0WU
KARPAS-45 NF7RVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnvTWM2OD16ND62PVkzKM7:TR?= NGPiVVFUSU6JRWK=
BE-13 NGrrOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y2cmlEPTB;OUmuNFQ4PyEQvF2= NUDBbnVtW0GQR1XS
GCIY M3u5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;oTWM2OD17OT6wPVU1KM7:TR?= M1nNN3NCVkeHUh?=
BV-173 M3LBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLzcYNKSzVyPUGwNE4{OjVizszN MYjTRW5ITVJ?
LB2518-MEL M37ZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M321fGlEPTB;MUCwMlc5QSEQvF2= NXXZT|MxW0GQR1XS
KS-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFyMT62N|kh|ryP NVW0[ZI1W0GQR1XS
MOLT-16 NIS4eGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7DcVVKSzVyPUGwOE46QDZizszN NV3CdnZ3W0GQR1XS
NCI-H1770 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFyOD63PFQh|ryP MUjTRW5ITVJ?
NCI-H82 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnntTWM2OD1zMUCuPVc3KM7:TR?= MnjkV2FPT0WU
NCCIT NITlOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nrTmlEPTB;MUGyMlUzQSEQvF2= M{nrXnNCVkeHUh?=
KALS-1 NXKx[lcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFzNT65OFEh|ryP MVLTRW5ITVJ?
LB2241-RCC MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTFzNj62O|kh|ryP NXvYcHZ3W0GQR1XS
HH NVf6bY5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXqyV|A2UUN3ME2xNVcvOzl3IN88US=> M3\rWnNCVkeHUh?=
HD-MY-Z MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFzOD60PFgh|ryP M2rIXnNCVkeHUh?=
EB-3 NX;Ic4pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn6UmdSUUN3ME2xNlMvODl2IN88US=> M3jLSnNCVkeHUh?=
BL-70 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS5[GhmUUN3ME2xNlMvOTJ5IN88US=> MlPOV2FPT0WU
K-562 MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvjOGhKSzVyPUGyOk4zPDVizszN MnvvV2FPT0WU
HT-144 NXvETGdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHpOHRoUUN3ME2xN|MvOTZ2IN88US=> Mn\qV2FPT0WU
PF-382 M1Ttb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4mxR2lEPTB;MUO0MlM3OSEQvF2= NG\lS|dUSU6JRWK=
RPMI-8226 NYPhZ3dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi3TWM2OD1zM{WuNFQ2KM7:TR?= MX7TRW5ITVJ?
NCI-H1355 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF|NT61PFch|ryP MoXoV2FPT0WU
LXF-289 M2\iSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXCeHJKSzVyPUGzPU44QDFizszN MYjTRW5ITVJ?
NCI-H69 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPmTWM2OD1zNEKuPVMzKM7:TR?= M{TIcXNCVkeHUh?=
SK-MEL-1 MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH4WXFHUUN3ME2xOFcvOTNizszN MX\TRW5ITVJ?
KARPAS-299 NFizVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jaXGlEPTB;MUS5MlEzKM7:TR?= NILIeFRUSU6JRWK=
GB-1 M1fFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu3Z3dKSzVyPUG0PU4{OjJizszN M2ezcnNCVkeHUh?=
CMK MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzH[Hl{UUN3ME2xOFkvPTF3IN88US=> MnjMV2FPT0WU
MPP-89 M3;QT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF3Nj6wN|Uh|ryP MmTEV2FPT0WU
KU812 NFPh[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33iNGlEPTB;MU[xMlkxOiEQvF2= NIHXTHNUSU6JRWK=
REH M3LIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF4Mj6xNlUh|ryP MUjTRW5ITVJ?
NEC8 NWDwWYhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\VTWM2OD1zNkWuNFI3KM7:TR?= MlXUV2FPT0WU
KP-N-YS M{\hXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHHeYJKSzVyPUG2PE4{QTVizszN MlnuV2FPT0WU
Ramos-2G6-4C10 NVfh[XdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO1Rm9KSzVyPUG2PU46OTVizszN MXPTRW5ITVJ?
Becker MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jZNGlEPTB;MUe0MlE5KM7:TR?= MUPTRW5ITVJ?
LB647-SCLC NGXmcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF36N41KSzVyPUG3OU45PDVizszN MkfUV2FPT0WU
LU-139 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn5TWM2OD1zN{iuNFE6KM7:TR?= M1;XW3NCVkeHUh?=
QIMR-WIL MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfLN3Z6UUN3ME2xO|kvPjR4IN88US=> NH72ZmtUSU6JRWK=
NCI-H1395 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDQTW1KSzVyPUG3PU46QTZizszN M4H1[XNCVkeHUh?=
NOMO-1 Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7ZOpFoUUN3ME2xPFIvQDVizszN NUja[W5OW0GQR1XS
GI-ME-N MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTF6Nz65Olkh|ryP M3L2fnNCVkeHUh?=
KMS-12-PE Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzYblJKSzVyPUG4PU4zPzNizszN NVrheng{W0GQR1XS
Daudi NY\jWmhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3RTXplUUN3ME2xPVEvOTJ6IN88US=> MVzTRW5ITVJ?
LB996-RCC MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzNZ40xUUN3ME2xPVEvPjl7IN88US=> NULBVZVKW0GQR1XS
NCI-H2107 M164eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf1WWpKSzVyPUG5N{44OzlizszN Mn\BV2FPT0WU
SK-PN-DW NHfWbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7ueGhKSzVyPUG5OE44OTlizszN NY\FZ5BnW0GQR1XS
MC-CAR M3rST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDGTWM2OD1{MEKuNlU{KM7:TR?= MVHTRW5ITVJ?
SNB75 NI\0fHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJ{MT65OEDPxE1? NX\LfG41W0GQR1XS
ES4 MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfIN3JKSzVyPUKyN{44QDNizszN NUPyOpc6W0GQR1XS
KARPAS-422 MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfr[|hKSzVyPUKyPE4{PTJizszN M1fERnNCVkeHUh?=
NCI-H1648 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DFVWlEPTB;MkK5MlQ5QSEQvF2= NXzlW45RW0GQR1XS
ES6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LnbGlEPTB;MkO5MlQ{KM7:TR?= M{TCeHNCVkeHUh?=
KNS-81-FD NHHWTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\2UWlEPTB;MkSxMlE6PyEQvF2= NWexN2h3W0GQR1XS
JAR NV;uXXBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLvNnZKUUN3ME2yOVYvOjJ3IN88US=> NHvj[|FUSU6JRWK=
NB1 M3fOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPvTWM2OD1{NkCuOVE3KM7:TR?= Mmq0V2FPT0WU
D-336MG NGDi[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJ4MD62PVgh|ryP M4HX[XNCVkeHUh?=
BC-3 Mk\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LwVmlEPTB;Mk[1MlE4QCEQvF2= Mn7uV2FPT0WU
HCC2218 M{\hbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJ4Nj60NVUh|ryP MoHMV2FPT0WU
TE-9 NHfTbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHZTWM2OD1{Nk[uOlI4KM7:TR?= NIW3fHJUSU6JRWK=
LB1047-RCC NE\RcYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJ4Nj63OVMh|ryP Mk\wV2FPT0WU
CTB-1 M1jUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfpUlFNUUN3ME2yOlkvQTd|IN88US=> M{nhe3NCVkeHUh?=
NB7 M2LFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD6TWM2OD1{N{Gg{txO M3j1WXNCVkeHUh?=
ST486 NE\VeXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJ5Nz60NVIh|ryP NVL4R496W0GQR1XS
HCC1187 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrjfFhuUUN3ME2yPFIvQDFzIN88US=> NY\OfpZuW0GQR1XS
NCI-SNU-16 NWjxU2FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUm2N2t3UUN3ME2yPFQvOjR6IN88US=> MXXTRW5ITVJ?
COR-L279 MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjUeXhFUUN3ME2yPVEvPTh2IN88US=> NHXJXI5USU6JRWK=
ES8 MmPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rneGlEPTB;Mkm0MlE5OiEQvF2= MmWwV2FPT0WU
U-698-M NUX4VGFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPX[XhKSzVyPUK5PE4zPDNizszN MWTTRW5ITVJ?
HEL NHHNcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXP0V3BmUUN3ME2zNFkvOTR7IN88US=> M4\ke3NCVkeHUh?=
KINGS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrEdnJKSzVyPUOxNE43PzRizszN NVPKWHNIW0GQR1XS
KY821 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXCbGpKSzVyPUOzOk42QTVizszN Mlr5V2FPT0WU
MZ1-PC NWr3fJoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\LSmlEPTB;M{S1MlYyQCEQvF2= NHXzS2JUSU6JRWK=
LS-411N NVr6PZc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTN3ND62OkDPxE1? MlrTV2FPT0WU
SIG-M5 MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\lRmlEPTB;M{W5Mlc5OiEQvF2= MkPCV2FPT0WU
HT MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\RWFRRUUN3ME2zOlcvPzFzIN88US=> NEm1[|VUSU6JRWK=
HC-1 MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjWbYlKSzVyPUO2O{44QDdizszN Ml3BV2FPT0WU
NCI-H1694 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj5TWM2OD1|N{KuPVM1KM7:TR?= NWO3OFhCW0GQR1XS
BB65-RCC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33iNGlEPTB;M{e2MlI1PSEQvF2= NV7EXYI3W0GQR1XS
HAL-01 MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHvfIlmUUN3ME2zO|kvQDN6IN88US=> NFvqS5lUSU6JRWK=
ARH-77 M3\pWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrxN5VEUUN3ME2zPVQvODB6IN88US=> M3q4UHNCVkeHUh?=
MZ7-mel MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn0dW53UUN3ME2zPVcvOjN|IN88US=> NE[3UGxUSU6JRWK=
SIMA MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTRyMz65N|Mh|ryP M2O3[nNCVkeHUh?=
DG-75 MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\EW2lEPTB;NEG1MlY6QCEQvF2= NWf0UHltW0GQR1XS
HUTU-80 NWe0e4ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTTTWM2OD12MUmuNVg2KM7:TR?= MkXNV2FPT0WU
KNS-42 M3:yXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HlNWlEPTB;NEK1MlgyPSEQvF2= NWjwbGtJW0GQR1XS
SH-4 NHK1fnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTR{Nz61OlUh|ryP MYDTRW5ITVJ?
L-540 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnrfnVCUUN3ME20N|EvODNzIN88US=> MXHTRW5ITVJ?
NB10 M37LcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjKXoU3UUN3ME20OFEvOjN2IN88US=> NEHPUGlUSU6JRWK=
ES1 M36zT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\nTWM2OD12NUKuO|U{KM7:TR?= NWL3cIczW0GQR1XS
KMOE-2 M2C5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPYUHZ{UUN3ME20OVYvPzFzIN88US=> MlrqV2FPT0WU
MC116 NWPiTJd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf5e4FCUUN3ME20OVgvOTF4IN88US=> NVj0OVhSW0GQR1XS
RCC10RGB NYHnWG1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq0[oNKSzVyPUS2NE4xODVizszN NWHOcpFJW0GQR1XS
RL95-2 M3zGTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf0clBKSzVyPUS2NE4zOzdizszN MknCV2FPT0WU
Raji NFvqNohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;NeWtLUUN3ME20OlgvOTR|IN88US=> M2qw[XNCVkeHUh?=
CAS-1 MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:1TWM2OD12N{KuNFc{KM7:TR?= NXLkNlYyW0GQR1XS
Calu-6 NFS4N|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4C2PWlEPTB;NEe1MlI3PSEQvF2= M3;S[HNCVkeHUh?=
KG-1 NFXLdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\wOmlEPTB;NEe4MlQ1KM7:TR?= NVHofG43W0GQR1XS
LB771-HNC NHjFfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDHdVRCUUN3ME20PFIvOjN{IN88US=> MoHGV2FPT0WU
ACN NIOzeYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LweGlEPTB;NEmzMlU6QSEQvF2= MX\TRW5ITVJ?
KM12 NFPzdlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTR7Nj61PFkh|ryP NYTqO3JHW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID